|
|
Volumn 22, Issue 3, 2016, Pages 222-224
|
|
Group mentality: Determining if targeted treatments really work for cancer
a
a
NONE
(United States)
|
|
Author keywords
[No Author keywords available]
|
|
Indexed keywords
ANTINEOPLASTIC AGENT;
BIOLOGICAL MARKER;
LENALIDOMIDE;
ARTICLE;
CANCER CENTER;
CANCER CHEMOTHERAPY;
CANCER INCIDENCE;
CANCER PATIENT;
CANCER REGISTRY;
GENE MUTATION;
HUMAN;
MALIGNANT NEOPLASTIC DISEASE;
MOLECULARLY TARGETED THERAPY;
MULTIPLE MYELOMA;
NEXT GENERATION SEQUENCING;
PERSONALIZED MEDICINE;
PRIORITY JOURNAL;
TREATMENT OUTCOME;
TREATMENT RESPONSE;
ART;
COOPERATION;
DNA SEQUENCE;
FACTUAL DATABASE;
GENETICS;
HIGH THROUGHPUT SEQUENCING;
METHODOLOGY;
NEOPLASMS;
COOPERATIVE BEHAVIOR;
DATABASES, FACTUAL;
HIGH-THROUGHPUT NUCLEOTIDE SEQUENCING;
HUMANS;
MOLECULAR TARGETED THERAPY;
NEOPLASMS;
PRECISION MEDICINE;
RESEARCH DESIGN;
SEQUENCE ANALYSIS, DNA;
TREATMENT OUTCOME;
|
|
EID: 84978682921
PISSN: 10788956
EISSN: 1546170X
Source Type: Journal
DOI: 10.1038/nm0316-222 Document Type: Article |
|
Times cited : (9)
|
|
References (0)
|
